本文目录一览：
南京的医疗水平，列举南京什么医院看什么病厉害？分别说南京人民医院、南京鼓楼医院、南京军区总院
到百度上搜“复旦版最佳医院排行榜”你就能看到医院排名以及每个医院科室的全国排名。
请大家帮忙翻译这段话 谢谢
Introduced on behalf of the enterprise
I, on behalf of the enterprise-based R D outsourcing
Nanjing Chuanbo Biotechnology Co., Ltd. in August 2003 incorporated in the high-tech zones, with a registered capital of 12,000,000 yuan, is a Ph.D. from abroad and domestic scientists co-founder of the biotechnology business. Chuanbo to have a biological foreign experts and overseas students as the main body and doctorate or master's degrees composition of the technical backbone of the team. The company is committed to research and development of anti-antibody protein phosphorylation, after 3 years of research and development, has succeeded in building a development of the anti-protein phosphorylation antibody technology platform, has developed 17 kinds of cell signaling pathway in the 638 kinds of anti-phosphorylation Protein antibodies, 73 of which for the first time on the international success of the development of the antibody products, products have been sold in the United States, Canada, Britain, France, Germany and Japan more than 20 countries. Annual output value reached 125 million. Science and Technology Development Zone Company and established a joint venture center "of the Nanjing International Antibody Engineering Research Center," the company for long-term development strategy that antibody drug research platform for international cooperation.
Second, the production of medical equipment on behalf of the enterprise
Minimally invasive Nanjing Medical Technology Co., Ltd. specializes in interventional stent lumen, a one-time sterile digestive endoscope, and so on endoscopic biopsy forceps the annex to the research and development of products and production sales. Own more than 10 patents, the Ministry of Health is "100 10-year plan to" bear the unit, China is the birthplace of the one-time biopsy forceps. The company has 1500 in line with the GMP requirements of 10,000 square meters clean workshop, is currently the only shop in the clean production of the stent business. Company sales in 2007 amounted to 100,000,000 yuan.
Third, medicine, health products on behalf of the production-oriented enterprises
Kang Hae Medicine Co., Ltd. Nanjing (formerly Nanking Zhenzhong Biological Engineering Co., Ltd.), the main product is Lentinan Nanjing in a row to support the eight years of their own intellectual property rights of high-tech products. The products have more than 80% of the domestic market, with an annual output capacity of 650,000, the output value reached 80,000,000 yuan. The other two companies - taxol liposomes and selegiline hydrochloride in the next two years will create a production value of 50,000,000 yuan. The company is "Lentinan freeze-dried powder", "amifostine injection", "paclitaxel liposome components" has been an international PCT patent applications and has the United States, Japan, Russia, India, Thailand, the European Union Multi-national patent applications.
High-tech Zone of bioengineering and medicine industry with the times, the industry continues to prosper and grow in 2010 and bio-medical engineering science and technology park planning area will be 5.2 square kilometers, 200 enterprises to join in annual sales 20,000,000,000 yuan . Chinese medicine and bio-technology park for a leading innovation-driven, and increase input in research funding, to foster a number of market competitiveness and self-development capacity of the backbone of the new entity; at the same time establish and improve the research and development, pilot production technology platform. With mice research advantage of the resources of the library resources, biological targeting information technology, biomedical engineering, gene therapy technology to carry out industrialization of research work, at home and abroad to introduce genetic engineering-related fields of research and development institutions to further biomedical park in Nanjing to play the "three drug "Model Base of new drugs and the role of R D base, to build a unique national biomedical research base.
Focus on the future development of the field
① biological information technology, bio-chip technology, biomedical engineering, gene therapy, cell therapy, such as the industrialization of research. Focus on the development of bio-informatics research and development platform, biological diagnostic chips, cellular immune therapy drugs, monoclonal antibody diagnostic reagents, genetic engineering drugs and vaccines and other products.
② Chinese medicine and natural medicine quality standard certification technology; ingredient extraction, separation, purification, micro technology; active ingredients of Chinese medicine screening, the study of lead compounds, controlled-release technology of proprietary Chinese medicines, transdermal absorption of technology and targeted drug delivery technology And the development of Chinese medicine capsules, effervescent tablets, injections, pills, tablets, oral solution, and other new agents.
③ priority to the development of pharmaceutical chemical release, controlled release, targeted drug delivery technology and other modern technology. For cardiovascular disease, cancer, diabetes, autoimmune disease, kidney disease and hepatitis, multiple illnesses, development, with the introduction of advanced technology at home and abroad of new drugs.
电化学介入配合粒子支架治疗 怎么做？要操作过程。
仪器设备
电化学治疗应用北京航空航天大学与中国原子能科学研究院生产的BA91微电脑控制双路输出电化学治疗仪。使用管状铂金丝电极,电极长度3. 0、5. 0、7. 0cm三种。支架采用南京微创医学科技有限公司产MTN型钛镍形状记忆加膜双喇叭支架。使用通用食管支架置入器置入肿瘤狭窄段。
实验方法
手术切除之食管癌和贲门癌离体标本,病变长度在4~6cm,肿瘤浸润管壁一周,厚度1. 0~1. 5cm。在肿瘤狭窄段置管状电极,施加电压5~8V,电流40~70mA,量达1000库仑时观察标本并行病理组织学检查。大体标本见肿瘤组织表面溶解坏死,部分呈胶冻状。组织学检查见电极附贴处癌巢大片凝固坏死达浅肌层,深肌层仍可见癌巢,食管固有膜和贲门浆膜完整无坏死。标本置入支架扩张后食管无穿孔破裂。
操作方法
用0. 1%的丁卡因喷雾鼻腔和咽部。经鼻腔或口腔放置管状电极至狭窄段上方。嘱患者吞一口稀钡,在立位透视下将电极置于狭窄段。本组12例由于狭窄严重,电极置入困难,我们采用先由管状电极的中央孔置入泥鳅导丝,在监视器下操作直到导丝进入胃内,然后在导丝引导下推置电极于狭窄处。正确联接电化学治疗仪,逐渐将电压调至6~8V,电流50~120mA,用电量500~1000库仑,时间90~160min。治疗过程中监护仪监护心电图、血压、心率、血氧饱和度等生命体征。完成预定电量,拔除电极后给患者服用“消炎合剂”,配法为500ml生理盐水中加庆大霉素16×104u,地塞米松磷酸钠注射液10mg,山莨菪碱20mg混合而成。2~3周选择较病灶范围长4cm的带膜镍钛记忆合金支架。放置前肌注安定10mg, 654-2 10mg。口服造影剂在透视下确定病变范围。对狭窄严重者用8~12mm球囊扩张,以利于支架置入。
南京微创医学科技有限公司 怎么样
别去，里面管理差的一塌糊涂，每月都不按时发工资，你想想看这种企业能去嘛。
南京微创医学科技股份有限公司怎么样？
南京微创医学科技股份有限公司是2000-05-10在江苏省南京市注册成立的股份有限公司(中外合资、未上市)，注册地址位于南京高新开发区高科三路10号。
南京微创医学科技股份有限公司的统一社会信用代码/注册号是913201006089812733，企业法人隆晓辉，目前企业处于开业状态。
南京微创医学科技股份有限公司的经营范围是：医疗器械的研发、生产与销售（凭许可证所列事项生产经营）；与本企业业务相关的产品及技术的进出口业务（不涉及国营贸易管理商品，涉及配额、许可证管理商品的，按国家有关规定办理申请）；消毒灭菌服务；企业管理咨询服务；自有房屋及设备租赁。（依法须经批准的项目，经相关部门批准后方可开展经营活动）。本省范围内，当前企业的注册资本属于一般。
南京微创医学科技股份有限公司对外投资5家公司，具有0处分支机构。
通过百度企业信用查看南京微创医学科技股份有限公司更多信息和资讯。
